XPH — State Street SPDR S&P Pharmaceuticals ETF
Healthcare Ranked #175 of 458 tracked ETFs · Issued by State Street Investment Management
XPH Price Performance — Growth of $10,000
Value of a $10,000 investment in XPH over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
XPH Drawdown
The "underwater" chart: XPH's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in XPH?
See what a lump sum in XPH would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The State Street SPDR S&P Pharmaceuticals ETF is a healthcare-focused fund issued by State Street Investment Management with $524 million in assets. It holds an overall rank of #175 out of 458 tracked ETFs and sits at number 8 within its category of 11 funds. The fund carries a B grade with a score of 66.0/100 and an expense ratio of 0.35%, which is slightly below the category median of 0.36%. Its dividend yield of 0.44% trails the category median of 0.98%, indicating a lower income profile relative to peers. The top ten holdings comprise 28.9% of assets, with the largest position attributed to State Street Global Advisors at 8.6%.
The fund has delivered a 1-year return of +29.81%, outperforming the category median of +24.88%, though recent short-term performance shows a -5.57% decline over the last month. Price action currently sits at 56.4% of its 52-week range, reflecting a $62.70 valuation against a high of $74.35 and a low of $47.60. The rating has remained unchanged at grade B across the last 35 tracked days, suggesting stability in its assessment. Historical data is available for 3.0 years, providing a limited but established track record for analysis. The divergence between the strong annual gain and recent monthly losses highlights a volatile short-term trend.
With a beta of 0.68, the ETF has exhibited lower sensitivity to market movements compared to the broader index. Annualized volatility stands at 23.52%, which is classified as High, while the maximum drawdown reached -23.57%. A Sharpe ratio of 1.06 suggests that the fund has generated reasonable risk-adjusted returns despite the elevated volatility. Liquidity is moderate, with an average daily volume of 166,839 shares. These metrics collectively describe a fund that has experienced significant price swings but has maintained a positive risk-adjusted performance profile.
AI-generated summary based on the data on this page.
XPH Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | State Street Global Advisors | 8.58% | $37M |
| 2 | Definium Therapeutics Inc | 3.09% | $13M |
| 3 | MBX Biosciences Inc | 2.72% | $12M |
| 4 | Alumis Inc | 2.14% | $9M |
| 5 | AtaiBeckley Inc | 2.13% | $9M |
| 6 | Trevi Therapeutics Inc | 2.12% | $9M |
| 7 | Enliven Therapeutics Inc | 2.09% | $9M |
| 8 | Amylyx Pharmaceuticals Inc | 2.04% | $9M |
| 9 | VeraDermics Inc | 2.02% | $9M |
| 10 | Ligand Pharmaceuticals Inc | 1.94% | $8M |
Holdings as of 2026-06-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 28.9% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how XPH's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With XPH
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with XPH's top 10 — SPDW overlaps most, holding 1 of the same companies as XPH's top 10 (8.6% of XPH's assets).
| ETF | Name | Shared Companies | XPH Weight | Examples |
|---|---|---|---|---|
| SPDW | State Street SPDR Portfolio Developed World ex-US ETF | 1 | 8.6% | State Street Global Advisors |
| SPEM | State Street SPDR Portfolio Emerging Markets ETF | 1 | 8.6% | State Street Global Advisors |
| SDY | State Street SPDR S&P Dividend ETF | 1 | 8.6% | State Street Global Advisors |
| KRE | State Street SPDR S&P Regional Banking ETF | 1 | 8.6% | State Street Global Advisors |
| JNK | State Street SPDR Bloomberg High Yield Bond ETF | 1 | 8.6% | State Street Global Advisors |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.96% (as of 2026-10-22) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 19.03 (as of 2026-10-22) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.75% (as of 2026-09-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What XPH's Fees Cost You
XPH charges an expense ratio of 0.35% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
XPH Dividend Income Estimator
XPH currently yields 0.44%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
XPH Liquidity, Domicile & Tax Treatment
Liquidity: Average daily volume is 167K/day. Higher volume and a larger fund generally mean lower round-trip trading costs. AUM of $524M provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: XPH is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
XPH Performance History
| Period | Return |
|---|---|
| 1-Day | -2.46% |
| 1-Week | +1.39% |
| 1-Month | -5.57% |
| 3-Month | -8.46% |
| 6-Month | +9.34% |
| YTD | +13.81% |
| 1-Year | +29.81% |
| 3-Year | +82.50% |
How XPH Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #31 | B+ |
XLV | State Street Health Care Select Sector SPDR ETF | +24.88% | 0.08% | $43.4B |
| #36 | B+ |
VHT | Vanguard Health Care Index Fund ETF Shares | +24.24% | 0.09% | $21.8B |
| #64 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +24.43% | 0.084% | $3.54B |
| #100 | B |
IBB | iShares Biotechnology ETF | +35.23% | 0.44% | $11.2B |
| #106 | B |
XBI | State Street SPDR S&P Biotech ETF | +39.94% | 0.35% | $10.4B |
| #125 | B |
IYH | iShares U.S. Healthcare ETF | +24.20% | 0.37% | $3.96B |
| #140 | B |
PPH | VanEck Pharmaceutical ETF | +27.00% | 0.36% | $1.02B |
| #175 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +29.81% | 0.35% | $524M |
| #209 | C |
ARKG | ARK Genomic Revolution ETF | +57.54% | 0.75% | $2.22B |
| #297 | C |
IHF | iShares U.S. Healthcare Providers ETF | +19.55% | 0.37% | $1.36B |
| #424 | D |
IHI | iShares U.S. Medical Devices ETF | -11.17% | 0.37% | $3.45B |